Ebola virus vaccines: An overview of current approaches
Ebola hemorrhagic fever is one of the most fatal viral diseases worldwide affecting humans and nonhuman primates. Although infections only occur frequently in Central Africa, the virus has the potential to spread globally and is classified as a category A pathogen that could be misused as a bioterrorism agent. As of today there is no vaccine or treatment licensed to counteract Ebola virus infections. DNA, subunit and several viral vector approaches, replicating and non-replicating, have been tested as potential vaccine platforms and their protective efficacy has been evaluated in nonhuman primate models for Ebola virus infections, which closely resemble disease progression in humans. Though these vaccine platforms seem to confer protection through different mechanisms, several of them are efficacious against lethal disease in nonhuman primates attesting that vaccination against Ebola virus infections is feasible.
Available from: Hasna Amdiouni
- "Until now, there are a number of interesting reviews on the virology of Ebola viruses, ecology and vaccine development  . This paper is an review which shows biological aspects of Ebola virus, transmission with focusing on reservoirs hosts, the most recents Ebola virus outbreaks, clinical features, symptoms of Ebola, diagnosis tests, prevention and treatment. "
[Show abstract] [Hide abstract]
ABSTRACT: Filoviruses, including Ebola and Marburg viruses, are recognized as a significant warning to
public health. They are zoonotic agents with bats as primary reservoir. Those viruses can cause
severe human infection with hemorrhagic syndrome leading to death. The mortality rate can
be higher than 90%. In West Africa, recent Ebola virus outbreak occurred in March 2014, has
caused more than 8 300 infections with more than 4 000 deaths. That shows the critical state
of this country, and the critical context in worldwide. In order to fight this deadly scourge,
it is necessary to understand the epidemiology of disease and to establish a good diagnosis
protocols and protective measures. In recent decades, traditional techniques of virus isolation
are replaced by molecular biology techniques which are faster, more sensitive and specific.
Until now, no specific Ebola virus treatment or vaccine but many studies are in progress with
Available from: jgv.sgmjournals.org
- "), and vaccine development is under way (Marzi & Feldmann, 2014). "
[Show abstract] [Hide abstract]
ABSTRACT: On the 23rd March 2014, the WHO issued its first communiqué on a new outbreak of Ebola virus disease (EVD) which began in December 2013 in Guinée Forestière (Forested Guinea), the eastern sector of the Republic of Guinea. Located on the Atlantic coast of west Africa, Guinea is the first country in this geographical region in which an outbreak of EVD has occurred, leaving aside the single case reported in Ivory Coast in 1994. Cases have now also been confirmed across Guinea as well as in the neighbouring Republic of Liberia. The appearance of cases in the Guinean capital, Conakry, and the transit of another case through the Liberian capital, Monrovia, presents the first large urban setting for EVD transmission. By 20th April 2014, 242 suspected cases had resulted in a total of 147 deaths in Guinea and Liberia. The causative agent is now identified as an outlier strain of Zaire ebolavirus (EBOV). The full geographical extent and degree of severity of the outbreak, its zoonotic origins and its possible spread to other continents are sure to be subjects of intensive discussion over the next months.
Journal of General Virology 05/2014; 95(Pt_8). DOI:10.1099/vir.0.067199-0 · 3.18 Impact Factor
Available from: Louis Valiquette
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale / AMMI Canada 05/2014; 25(3):128-9. · 0.69 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.